First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

NCT06121401 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

190

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Ovarian Epithelial

Interventions

DRUG: Olaparib
DRUG: Bevacizumab

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]